ArticleMMWR. Morbidity and mortality weekly report2023
Progress Toward Poliomyelitis Eradication - Worldwide, January 2021-March 2023.
Article in MMWR. Morbidity and mortality weekly report, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 54 citations in OpenAlex.
- Persistence of immunity following a single dose of inactivated poliovirus vaccine: a phase 4, open label, non-randomised clinical trial.The Lancet. Microbe · 2023Trial
- Review
- The global threat of vaccine-preventable neurological diseases.Nature reviews. Neurology · 2026Review
- Overcoming barriers to polio eradication in challenging subnational geographies: lessons from South Khyber Pakhtunkhwa, Pakistan, 2022-2024.Frontiers in public health · 2026Article
- Editorial: Eradicating polio in Pakistan and other countries in the Eastern Mediterranean region: epidemiology, surveillance, and immunization.Frontiers in public health · 2026Article
- Tracking poliovirus through wastewater: environmental surveillance insights from Haïti (2020-2023).Applied and environmental microbiology · 2025Article
- Characterization of a Sabin-like type 2/3 recombinant poliovirus with a triple nucleotide deletion in the VP1 region isolated from sewage.Virology journal · 2025Article
- Article
- Poliomyelitis dynamics with fractional order derivatives and deep neural networks.Scientific reports · 2025Article
- Article
- Article
- Development and validation of a sensitive method to quantify a poorly ionized drug, pocapavir, in C57BL/6 mouse plasma.Bioanalysis · 2025Article
- Updates on the polio surveillance action plan's key performance indicators: East and Southern African countries (January 2022 to December 2023).The Pan African medical journal · 2025Article
- Polio eradication: A perspective from the UK.New microbes and new infections · 2024Article
- Re-emergence of vaccine-derived polio in the demographic Republic of Congo: Causes and consequences.New microbes and new infections · 2024Review
- Risk Assessments for Type 1 Wild Poliovirus and Type 2 Vaccine-Derived Poliovirus Importation and Transmission - China, 2023.China CDC weekly · 2024Article
- Progress Toward Poliomyelitis Eradication - Pakistan, January 2023-June 2024.MMWR. Morbidity and mortality weekly report · 2024Article
- Article
- Article
- Progress Toward Poliomyelitis Eradication - Worldwide, January 2022-December 2023.MMWR. Morbidity and mortality weekly report · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since the World Health Assembly established the Global Polio Eradication Initiative (GPEI) in 1988, two of the three wild poliovirus (WPV) serotypes (types 2 and 3) have been eradicated, and global WPV cases have decreased by more than 99.9%. Afghanistan and Pakistan remain the only countries where indigenous WPV type 1 (WPV1) transmission has not been interrupted. This report summarizes progress toward global polio eradication during January 1, 2021-March 31, 2023, and updates previous reports (1,2). In 2022, Afghanistan and Pakistan reported 22 WPV1 cases, compared with five in 2021; as of May 5, 2023, a single WPV1 case was reported in Pakistan in 2023. A WPV1 case was reported on the African continent for the first time since 2016, when officials in Malawi confirmed a WPV1 case in a child with paralysis onset in November 2021; neighboring Mozambique subsequently reported eight genetically linked cases. Outbreaks of polio caused by circulating vaccine-derived polioviruses (cVDPVs) can occur when oral poliovirus vaccine (OPV) strains circulate for a prolonged time in underimmunized populations, allowing reversion to neurovirulence (3). A total of 859 cVDPV cases occurred during 2022, an increase of 23% from 698 cases in 2021. cVDPVs were detected in areas where poliovirus transmission had long been eliminated (including in Canada, Israel, the United Kingdom, and the United States). In addition, cocirculation of multiple poliovirus types occurred in multiple countries globally (including Democratic Republic of the Congo [DRC], Israel, Malawi, Mozambique, Republic of the Congo, and Yemen). The 2022-2026 GPEI strategic plan targeted the goal of detecting the last cases of WPV1 and cVDPV in 2023 (4). The current global epidemiology of poliovirus transmission makes the likelihood of meeting this target date unlikely. The detections of poliovirus (WPV1 and cVDPVs) in areas where it had been previously eliminated underscore the threat of continued poliovirus spread to any area where there is insufficient vaccination to poliovirus (3). Mass vaccination and surveillance should be further enhanced in areas of transmission to interrupt poliovirus transmission and to end the global threat of paralytic polio in children.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.